Document Detail


Antihypertensive effects of captopril and saralasin in essential and renal hypertension.
MedLine Citation:
PMID:  7041597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The antihypertensive effect of captopril and its mechanism of action were studied in patients with essential and renal hypertension. In mild essential hypertension (n = 12), during monotherapy with captopril (50 to 450 mg, 4 to 12 weeks) blood pressure was normalized in seven, improved in two and remained unchanged in three patients, plasma levels of active and acid-activatable inactive renin significantly increased and angiotensin II decreased, whereas no consistent changes in urinary kallikrein excretion occurred. In severe renal (n = 14) and essential (n = 9) hypertension, blood pressure was normalized in eight (seven with renal hypertension), improved in seven and unchanged in eight patients, when captopril (50 to 450 mg, 3 to 15 months) was added to the antihypertensive medication. In one patient with stenosis in a transplanted renal artery reversible renal failure occurred during captopril therapy possibly because of a steep initial decrease in blood pressure, although a toxic effect of the drug cannot be excluded. In another series of 12 renal and 8 essential hypertensive patients, a significant correlation between the acute effect of captopril (within 90 minutes) an saralasin on blood pressure was demonstrated (r=0.71, p less than 0.001). The change in blood pressure after either drug was significantly related to the initial plasma renin concentration. In conclusion, captopril seems to be an effective antihypertensive agent in essential and renal hypertension. Renal function should be monitored during captopril therapy. Our studies suggest that captopril decreases blood pressure by inhibiting the vasopressor action of the renin-angiotensin system.
Authors:
A Konrads; K A Meurer; W Hummerich; G Wambach; J Kindler; H Feltkamp; A Helber
Related Documents :
2843197 - Pharmacokinetics of single and consecutive doses of cilazapril and its depressor effect...
2580177 - Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combi...
11300367 - Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hy...
17057137 - Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overd...
3342727 - Reflux from ileum to colon in the dog. role of external ligamentous attachments.
11103187 - Effects of sevoflurane on hypoxic pulmonary vasoconstriction in anaesthetized piglets.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  49     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1982 Apr 
Date Detail:
Created Date:  1982-06-24     Completed Date:  1982-06-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1558-60     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / analogs & derivatives*
Captopril / therapeutic use*
Electrolytes / blood
Humans
Hypertension / drug therapy*
Hypertension, Renal / drug therapy*
Hypertension, Renovascular / drug therapy
Proline / analogs & derivatives*
Renin / blood
Renin-Angiotensin System / drug effects
Saralasin / therapeutic use*
Chemical
Reg. No./Substance:
0/Electrolytes; 11128-99-7/Angiotensin II; 147-85-3/Proline; 34273-10-4/Saralasin; 62571-86-2/Captopril; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Active and inactive renin after a single dose of captopril in hypertensive patients.
Next Document:  Increase in plasma aldosterone during prolonged captopril treatment.